Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium Complex-Reference-Cited by-同舟云学术

Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium Complex

Published:1999-12 Issue:12 Volume:43 Page:3001-3004
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tomioka Haruaki¹,Sato Katsumasa¹,Akaki Tatsuya¹²,Kajitani Hiroko¹,Kawahara Shin³,Sakatani Mitsunori⁴

Affiliation:

1. Department of Microbiology and Immunology1 and

2. Department of Dermatology,2 Shimane Medical University, Izumo, Shimane 693-8501,

3. National Sanatorium Minami-Okayama Hospital, Okayama 710-0304,3 and

4. National Sanatorium Kinki-Chuo Hospital, Osaka 591-8555,4 Japan

Abstract

ABSTRACT We compared the in vitro antimycobacterial activity of a new fluoroquinolone, HSR-903, with strong activity against gram-positive cocci with those of levofloxacin (LVFX), sitafloxacin (STFX), and gatifloxacin (GFLX). The MICs of the quinolones for Mycobacterium tuberculosis and Mycobacterium avium complex were in the order STFX ≈ GFLX < LVFX ≦ HSR-903 and STFX ≦ GFLX ≦ HSR-903 ≦ LVFX, respectively. HSR-903 effectively eliminated intramacrophagial M. tuberculosis , as did LVFX, and exhibited bacteriostatic effects against M. tuberculosis replicating in type II alveolar cells.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.43.12.3001

Reference29 articles.

1. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.;Alangaden G. J.;Clin. Infect. Dis.,1997

2. Mycobacterium tuberculosis invades and replicates within type II alveolar cells

3. Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers

4. Epidemiology of infection by nontuberculous mycobacteria

5. In-vitro activities of quinolones against mycobacteria.;Garcia-Rodriguez J. A.;J. Antimicrob. Chemother.,1993

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and antimicrobial susceptibility profiles of Mycobacterium abscessus and Mycobacterium massiliense pulmonary infection;Journal of Global Antimicrobial Resistance;2024-09

2. Recent Biochemical Advances in Antitubercular Drugs: Challenges and Future;Current Topics in Medicinal Chemistry;2024-08

3. The synergetic effect of sitafloxacin–arbekacin combination in the Mycobacterium abscessus species;Scientific Reports;2023-02-04

4. The Synergetic Effect of Sitafloxacin-Arbekacin Combination in the Mycobacterium abscessus Species;2022-12-21

5. Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity;Frontiers in Microbiology;2022-01-06